A Phase I Trial of AEG35156 Administered by 2-Hour Intravenous Infusion in Patients With Advanced Cancers
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2008
At a glance
- Drugs AEG 35156 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Aegera Therapeutics
- 20 Aug 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Nov 2005 New trial record.